Use of AI to develop health economic evidence for optimized patient access

For a thorough understanding of the AI journey in healthcare, and its potential to transform and improve evidence generation and market access, listen to Rito Bergemann, MD, PhD and Jacqueline Vanderpuye-Orgle, MSc, PhD in their HEOR Theater presentation at the ISPOR US event. AI and human intelligence will play an integral part in RWD analysis and HEOR evidence, and they discuss its growing importance for optimized patient access.

Return to Insights Center

Related Insights

Whitepaper

Optimizing Biosensor-based Trials

Feb 1, 2023

Article

How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022

Blog

Actigraphy advances a patient-first approach: Reduce patient burden — and make the most of valuable data

Oct 15, 2021

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Report

New Medicines, Novel Insights: Achieving patient-guided drug development

Oct 30, 2023

Blog

Highlights from ISMPP Asia Pacific Meeting 2021

Sep 20, 2021

Whitepaper

Addressing the Challenges of Artificial Intelligence used for Data Extraction in Systematic Literature Reviews

Mar 15, 2023

Playbook

Are you using real-world evidence?

Feb 1, 2023

Blog

Using ethical AI to streamline HEOR

Jan 26, 2024

Blog

Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression

Apr 23, 2024

Podcast

Decentrally Speaking | Episode 1: Optimizing Trial Inclusivity For Patients From Under-Represented Communities

Mar 22, 2022